Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drug Delivery Systems: Different Types

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Krüppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion.

Cancer letters·2017

Same author

Dynamics of multiple elements in fast decomposing vegetable residues.

The Science of the total environment·2017

Same author

Performing differential operation with a silver dendritic metasurface at visible wavelengths.

Optics express·2017

Same author

Optimal timing for the oral administration of Da-Cheng-Qi decoction based on the pharmacokinetic and pharmacodynamic targeting of the pancreas in rats with acute pancreatitis.

World journal of gastroenterology·2017

Same author

The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.

Journal of cellular biochemistry·2017

Same author

Preparation of Vascular Endothelial Cadherin Loaded-Amphoteric Copolymer Decorated Coronary Stents for Anticoagulation and Endothelialization.

Langmuir : the ACS journal of surfaces and colloids·2017

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

A pH/enzyme-responsive tumor-specific delivery system for doxorubicin.

Lei Dong¹, Suhua Xia, Ke Wu

¹State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, PR China.

|May 18, 2010

Summary

A novel pH/enzyme-responsive nanocomplex effectively delivers doxorubicin (DOX) specifically to tumors. This targeted delivery enhances anti-cancer activity while significantly reducing cardiotoxicity, offering a promising new formulation.

More Related Videos

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Experiment Videos

Last Updated: Jun 13, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Area of Science:

Biomedical Engineering
Nanotechnology
Drug Delivery Systems

Background:

Doxorubicin (DOX) is a potent anti-cancer drug but its use is limited by severe cardiotoxicity.
Developing targeted drug delivery systems is crucial to enhance efficacy and minimize side effects.

Purpose of the Study:

To develop a self-assembled, pH/enzyme-responsive nanocomplex for tumor-specific doxorubicin delivery.
To evaluate the enhanced anti-cancer activity and reduced cardiotoxicity of this novel formulation.

Main Methods:

Fabrication of dual-responsive nanocomplexes (CPX2) using cationic gelatin, polyGC-DOX, and pH-sensitive pegylated alginate.
Assessing doxorubicin release triggered by gelatinase (GA) and Dnase I at pH < 6.9.
Evaluating tumor-specific drug release using tumor homogenate supernatant (THS) versus plasma and liver homogenate supernatant (LHS).
In vivo biodistribution, anti-cancer efficacy, and cardiotoxicity studies.

Main Results:

CPX2 demonstrated pH/enzyme-dependent doxorubicin release, specifically triggered by THS.
In vivo studies confirmed tumor-specific drug accumulation and reduced drug levels in the heart and liver.
The formulation significantly enhanced anti-cancer activity (over 2x free DOX) and completely prevented high-dose DOX-induced mortality.
Reduced cardiotoxicity was observed compared to free doxorubicin.

Conclusions:

The developed nanocomplex provides a tumor-specific drug release mechanism.
This formulation offers a promising strategy to improve doxorubicin's therapeutic index by enhancing efficacy and reducing cardiotoxicity.
The easy-manufactured, cost-effective nature of the nanocomplex supports its potential clinical translation for doxorubicin and other anthracyclines.